ライフサイエンスコーパス: end

1 obic and polar amino acids at the C-terminal end.

2 lated (charged) with an amino acid at its 3' end.

3 ssembly and substrate release at the lagging end.

4 capture of the 12DR of the other transposon end.

5 the desire to control when and how life will end.

6 ing strand bias and low base quality at read ends.

7 truncates core histones at their N-terminal ends.

8 pproximately 10-20 nucleotides away from the ends.

9 mplex dynactin with dynamic microtubule plus ends.

10 ologies remain static after this process has ended.

11 To this end, anaerobic fungi in the rumen have been identified a

12 transposase binds specifically to the Muta1 ends and catalyzes excision through double strand breaks

13 otor that can accumulate at microtubule plus ends and induce pausing.

14 stable heterodimer that protects chromosome ends and regulates telomerase-mediated telomere extensio

15 To this end, apoptotic cells express specific eat-me signals, su

16 of (T2AG3)n lost from replicated chromosome ends as a single elongation event.

17 3-6 during adolescence, 6 months apart) and ending at mean age 35.1 years (SD 0.6; wave 10).

18 End binding protein 1 (EB1) is a key element in the comp

19 rd in vivo Furthermore, live-cell imaging of end-binding protein 3 tagged with EGFP (EB3-GFP) in prim

20 icrotubule network and the microtubule minus end-binding protein, Patronin.

21 Recruitment has ended, but follow-up is ongoing.

22 the complete binding region anchored at each end by hydrophobic interactions.

23 eads (fibrils) are capable of growing on the ends by seeding the refolding and incorporation of the n

24 res made of a higher molecular weight, ester end-capped PLGA displayed an osmotically induced/pore di

25 The use of amine end-capped polyynes as precursors to substituted push-pu

26 mide and perylene diimide electron acceptors end-capped with two guanine electron donors into crystal

27 However, when the DSB end contains a 3' protruding nonhomologous tail, Msh2 pr

28 c continuity between the proximal and distal ends declines with age.

29 remodeling at 6 months included decreases in end-diastolic (161 +/- 36 ml to 122 +/- 30 ml; p < 0.001

30 s, had higher indexed right ventricular (RV) end-diastolic (range 85-326 mL/m(2), mean 148 mL/m(2)) v

31 IUGR placentas displaying absent or reversed end-diastolic flow contained reduced myosin heavy chain,

32 lume: -4.3 [11.3] versus 7.4 [11.8], P=0.02; end-diastolic volume: -9.1 [14.9] versus 7.4 [15.8], P=0

33 at these landmarks and grow while their free ends diffuse.

34 However, the functional necessity of minus-end-directed movement along actin is unclear as the unde

35 mutant of MYO6, MYO6+, which undergoes plus-end-directed movement while retaining physiological carg

36 hat the edge lengths are given by the end-to-end distances between nodes.

37 oes by attaching them to dynamic microtubule ends during both polymerization and depolymerization of

38 Toward this end, embedding electronic-spin-based qubits within the f

39 End expiratory pressure dependent changes in airway cali

40 A 15-second end-expiratory occlusion and end-inspiratory occlusion,

41 The positive end-expiratory pressure level resulting in highest compl

42 Thereafter, three positive end-expiratory pressure levels were applied in a random

43 on, animals underwent a decremental positive end-expiratory pressure titration (steps of 2 cm H2O sta

44 est compliance during a decremental positive end-expiratory pressure trial after lung recruitment was

45 Peak inspiratory pressure, positive end-expiratory pressure, DeltaP, tidal volume, Cdyn, and

46 ent/derecruitment occurred when the positive end-expiratory transpulmonary pressure decreased below 2

47 The growing microtubule plus ends extend toward the cell's apex and base with a regio

48 d piwi-interacting RNA intermediates with 3' end extension, leading to severe reduction of mature piw

49 ermeability, and re-established perivascular end-feet astrocytes in symptomatic ALS mice may represen

50 at in mammalian cells, the formation of a 3' end for noncoding RNAs can be a complex process governed

51 he t-loop structure, thereby hiding telomere ends from double-stranded break repair and ATM signaling

52 ng the CNCs into a toluene solution of amine end-functionalized polystyrene are completely suppressed

53 -(CH2)2-, and a hydrophilic carboxylic acid end group are found to be the most effective at retardin

54 eparation process, the goal of separation by end group functionality was still achieved on the basis

55 t, was investigated in order to produce high end-group fidelity poly(propylene maleate).

56 d on the prey and body states most likely to end in successful capture.

57 hat older marine invasions have consistently ended in extinction.

58 Data collection ended in October 2016.

59 es (83%) reporting full recovery and 3 cases ending in death.

60 To this end, incorporation of suitable protein scaffolds for PSI

61 , where this mechanism would provoke a never-ending increasing mRNA synthesis rate in smaller daughte

62 A 15-second end-expiratory occlusion and end-inspiratory occlusion, separated by 1 minute, follow

63 ut prevents correct positioning of their CCA-ends into the PTC thus making peptide bond formation imp

64 When homology at the matched end is </=150 bp, efficient repair depends on the recomb

65 ides a long-distance interaction with the 5' end is unique.

66 break repair via the canonical nonhomologous end joining (c-NHEJ) pathway.

67 tion, which typically arise by nonhomologous end joining.

68 d-joining (NHEJ), and microhomology-mediated end-joining (MMEJ).

69 Non-homologous end-joining (NHEJ) is the most prominent DNA double stra

70 Nonhomologous DNA end-joining (NHEJ) is the predominant double-strand brea

71 homologous recombination (HR), nonhomologous end-joining (NHEJ), and microhomology-mediated end-joini

72 ge, which suppresses repair by nonhomologous end-joining and homologous recombination.

73 xynucleotidyl transferase-mediated dUTP nick-end labeling assay was performed, and intestinal inflamm

74 and help clarify how LIS1 promotes the plus-end localisation and cargo transport functions of dynein

75 ent termini of the glycan, with the reducing-end mannose residue ligated to Ca(2+) in a primary bindi

76 bound more intimately with its two reducing-end mannoses into the domain A binding site of CV-N than

77 e of mixing between isotopically distinct Cd end-members was confirmed by a Bayesian modeling approac

78 a reveal that mammalian RNAs can harbor a 5' end modification distinct from the classical m(7)G cap t

79 Here we sequence the genomes of an Early and End Neolithic dog from Germany, including a sample assoc

80 ing treatment), which were maintained at the end of 1 year follow-up in these five patients.

81 By the end of 1 year follow-up, normalisation of serum aminotra

82 cting between 47% and 56% less pollen by the end of 10 trials.

83 a-tetanus-acellular pertussis vaccine by the end of 15 months of age.

84 of people living with HIV in the country by end of 2013; (2) proportion of stage 1 ever diagnosed; (

85 f 2010 to 39 (71%) of 55 centres open at the end of 2014.

86 aordinary increase in air temperature at the end of 2015.

87 Telomeres are found at the end of chromosomes and are important for chromosome stab

88 Toward the end of each phase, we measured arterial blood gases, ins

89 The mean (SD) age at end of follow-up was 4.6 (0.40) years for the 61359 chil

90 ssure monitoring, and polysomnography at the end of follow-up.

91 for any secondary outcome at 4 weeks or the end of follow-up.

92 demonstrated what self-management support at end of life entails and how it is enacted in practice.

93 in patients with advanced disease and at the end of life.

94 DK1 promotes efficient SC destruction at the end of prophase I to ensure faithful inheritance of the

95 nd MMP9 were measured at baseline and at the end of the 6-week study period.

96 edge growth enhancement by one-third by the end of the century.

97 nucleotides 889 to 1289 encompassing the 3' end of the delta protein-coding gene.

98 n increase in home range overlap towards the end of the dry season.

99 At the end of the experiment some metabolites will have incorpo

100 ng allows a Vps4 subunit to join the growing end of the helix and engage the substrate, while hydroly

101 contents (TF) decreased by about 50% at the end of the in vitro GID.

102 onsisted of minimal alterations to the front-end of the instrument and provided better sensitivity, s

103 e, confirms that mutations in the N-terminal end of the kinase domain are more disruptive of protein

104 istory of the Fennoscandian Ice Sheet at the end of the last deglaciation ( approximately 13,200-12,0

105 h global glaciations and continued until the end of the Lomagundi carbon isotope excursion ca. 2,060

106 PABPN1-dependent ALYREF binding near the 3' end of the mRNA.

107 The assembly of PNNs coincides with the end of the period of heightened visual cortex plasticity

108 n of the C domain (up to 30 degrees ) at the end of the relatively immobile interdomain linker.

109 r-blocking hairpin (SBH) structure at the 5' end of the single guide RNA (sgRNA), which abrogates the

110 hotostability, (b) an N-methyl group at each end of the squaraine core that ensures fast macrocycle t

111 At the end of the study, echocardiography was repeated, with ad

112 first 6 months and were maintained until the end of the study.

113 isit of the follow-up, date of death, or the end of the study.

114 Median follow-up at the end of the trial on Nov 5, 2014, was 49.6 months in each

115 high-intensity CBT started treatment by the end of the trial, compared to 62% in supported cCBT and

116 ng the treatment period than at baseline and end of therapy, Z >/= -2.27, p </= .023.

117 become a problem for spruce and beech by the end of this century, but probably not for fir.

118 oth species that mutations at the C-terminal end of this epitope dramatically improve presentation to

119 ody (anti-HBs) titres above 10 mIU/mL at the end of treatment (five had maximum anti-HBs concentratio

120 At the end of treatment, morphological and biochemical analyses

121 ined virologic response at week 12 after the end of treatment.

122 ncentration from baseline (randomization) to end of treatment.

123 erphosphorylation of CTD Ser2 residues at 5' ends of genes that is conserved in yeast.

124 Telomeres, the protective ends of linear chromosomes, shorten throughout an indivi

125 trolling expression in joints versus growing ends of long bones.

126 lattice and to the shrinking plus and minus ends of microtubules.

127 dimerization and activation of Torso at the ends of the Drosophila embryo.

128 aracteristics of the regions at the terminal ends of two frequent types of large structural mosaic ev

129 United States, Mexico-NAM) to the projected end-of-century climate (2071-2100).

130 re then elastically registered to the single end-of-expiration NAC PET image.

131 Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) as

132 ospital services, and an increasing need for end-of-life care.

133 End-of-life decisions are not only common in the ICU but

134 cling strategies for future CM quantities in end-of-life vehicles (ELVs) are poorly understood, mainl

135 The study's treatment phase ended on August 31, 2013, and the analysis for the prese

136 Thus, end-on attachment provides geometry-specific molecular c

137 -associated PP1, plays a significant role in end-on conversion.

138 tential treatment for diabetic patients with end-organ complications.

139 Correlations of the end-period SFFQ were weaker when ASA24s were used as the

140 Both the end-Permian and end-Triassic mass extinctions also trigg

141 ignificantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%

142 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.8

143 ation between stent fracture and the primary end point (P=0.86) or with restenosis (P=0.53).

144 s compared between the 2 arms as the primary end point and overall survival (OS) as the secondary end

145 ing strategy was used for the second primary end point and the secondary end points in the final anal

146 s uncoupled as nucleosome sliding reaches an end point and this is controlled by the Ino80CTD.

147 Academic Research Consortium-2 early safety end point at 30 days was 7.4% with both devices with no

148 f complete remission and the composite renal end point did not differ significantly between groups.

149 he use of gamma-band ASSR as a translational end point in pro-cognitive drug discovery and early-phas

150 cy model supports use of PB-MRD as a primary end point in randomized clinical trials of chemoimmunoth

151 Use of this end point may expedite therapeutic development with the

152 0 to 0.99) and a lower risk of the composite end point of brain damage, nursing home admission, or de

153 sociated with increased risk of the combined end point of death or transplantation.

154 an follow-up of 3.9+/-2.4 years, the primary end point of death, transplant, or admission for heart f

155 ctors for RVAD implantation and the combined end point of RVAD or death within 14 days of LVAD were a

156 None of the secondary end point or day-30 all-cause mortality or heart failure

157 Digital polymerase chain reaction (dPCR) end point platforms directly estimate the number of DNA

158 The analysis of the primary end point showed noninferiority of the study device rela

159 The primary efficacy end point was a composite of adjudicated cardiovascular

160 The primary efficacy end point was change in serum phosphate concentration fr

161 The primary end point was daily combined symptom-medication scores d

162 The primary end point was death, myocardial infarction, or unstable

163 A primary cardiac end point was defined as symptomatic congestive heart fa

164 The primary end point was development of HGD or EAC.

165 The primary end point was dual: a composite of all-cause mortality a

166 The primary end point was event-free survival (with an event defined

167 The primary end point was freedom from repeat coronary revasculariza

168 Primary end point was hemodialysis independence at 3 months; sec

169 The primary safety end point was major adverse cardiac, cerebrovascular, an

170 The 30-day composite end point was not significantly different between suctio

171 The primary end point was overall response rate (ORR).

172 The primary end point was overall survival (OS) of patients who were

173 The primary end point was overall survival.

174 The primary end point was PFS; secondary end points included overall

175 The primary end point was the change in peak VO2 from baseline to 24

176 The primary end point was the detection of bone lesions at diagnosis

177 The primary end point was the development of asthma until age 12 yea

178 The primary end point was the identification of the maximum tolerate

179 The primary end point was the incidence of somatic mutations of the

180 The end point was the risk difference in the onset of new al

181 l phase (-126.3 minutes at 1-year open-label end point).

182 a particular new drug using an intermediate end point, such as MRD, would require confirmation using

183 ty score-matched populations was the primary end point.

184 sociated acute kidney injury was a secondary end point.

185 t and overall survival (OS) as the secondary end point.

186 more likely to achieve the primary efficacy end point: in trial A, 188 of 254 (74.0%) vs 21 of 254 (

187 A primary end-point event occurred in 68 of 1012 patients (6.7%) i

188 The primary end-point was the 2007 international working group compl

189 ological measures) with the probabilities of end points (e.g., death or system failure).

190 nic populations and for quantifying anatomic end points and response to therapy in AMD clinical trial

191 e second primary end point and the secondary end points in the final analysis.

192 Secondary end points included anatomic patency, adverse event rate

193 Secondary end points included cardiac magnetic resonance-determine

194 Secondary end points included change in body weight and cardiometa

195 Secondary end points included clinical outcomes (major adverse car

196 Secondary end points included disease-free survival and the cumula

197 Secondary end points included intraoperative and postoperative com

198 The primary end point was PFS; secondary end points included overall survival (OS), objective res

199 Secondary end points included overall survival and subgroup analys

200 Secondary end points included overall survival, distant metastasis

201 Secondary end points included repeat revascularization and a compo

202 The secondary end points included short-term weight loss, serum obesit

203 Secondary end points included the proportion of patients with at l

204 inical response criteria for the two primary end points than did those who received placebo.

205 variety of biological systems affect apical end points used in regulatory risk assessments, and with

206 Secondary end points were a 50% or greater reduction in mean migra

207 The two primary end points were a four-component composite of death thro

208 Clinical end points were AD dementia and any type of dementia aft

209 Secondary ischemic end points were also evaluated.

210 Secondary study end points were fractional flow reserve during vessel pa

211 Secondary end points were the number of telephone calls and emails

212 d progression-free survival were the primary end points.

213 a that capture financial and quality-of-life end points.

214 t significantly improve any of the secondary end points.

215 survival and overall survival were secondary end points.

216 to decline compared with control eyes at all end points.

217 uire confirmation using traditional efficacy end points.

218 dialysis independence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12

219 ess governed by the activities of various 3'-end polymerases and exonucleases.

220 ins transiently associate with free filament ends, preventing their growth and dynamically tethering

221 zymes studied caused significantly different end product functionality, presumably due to the differe

222 iption error rate estimated from mistakes in end product RNAs is 10-3-10-5.

223 tools towards the production of high quality end-product with increased bioactive properties without

224 role of the receptor for advanced glycation end products (RAGE) in neuroinflammation, neurodegenerat

225 The receptor for advanced glycation end products (RAGE) is highly expressed in various cance

226 Polymorphism observed within the aggregation end products of fibrils are known to arise due to micros

227 expression of proinflammatory cytokines, and end products of lipid oxidation had a synergistic effect

228 -2 and RAGE (receptor for advanced glycation end products) are not involved.

229 oform of the Receptor for Advanced Glycation End-products (nRAGE) in DSB-repair.

230 compounds formed during roasting, defined as end-products of Maillard reaction.

231 should be considered for alternative uses of end-products with high bioactivity.

232 the TRF2(TRFH) domain orchestrates telomere end protection and reveals how the phosphorylation statu

233 Cost-saving short (50-bp) single-end reads and Nextera (R) library preparation yield reli

234 diffusion, whereas Mre11 is required for DNA end recognition and nuclease activities.

235 omeric replication stress by stimulating DNA end resection and homologous recombination (HR).

236 ion but is thought to be dispensable for DNA end resection.

237 titute (NCI) Surveillance, Epidemiology, and End Results (SEER) database and data from the 10 clinica

238 4, using the Surveillance, Epidemiology, and End Results database.

239 data from the Surveillance, Epidemiology and End Results Program.

240 2 within the Surveillance, Epidemiology, and End Results registry.

241 al-era LUC emissions and suggests that upper-end scenarios for the extent of agricultural expansion b

242 To this end, seeds of selected species were collected from their

243 interchromosomal SVs from mate-pair and pair-end sequencing data.

244 converted to a sequencing library for paired-end sequencing.

245 ers functionalized with ligands on the chain ends, small molecule ligands, and palladium ions; polyMO

246 l gene expression in myocardial samples from end-stage CCC patients, compared to control samples from

247 In end-stage chronic kidney disease, the option of organ tr

248 tained myocardial samples from patients with end-stage heart failure at time of transplant, with or w

249 iomyocyte cellular activity in patients with end-stage HF after left ventricular assist device (LVAD)

250 The t-system in end-stage human HF presents a characteristic novel pheno

251 Treatment for end-stage kidney disease is a major economic challenge a

252 a heightened risk of developing chronic and end-stage kidney disease, an association that is largely

253 adult patients with cirrhosis and Model for End-Stage Liver Disease (MELD) score within 3 months of

254 k), but the Lille (P < 0.0001) and Model for End-Stage Liver Disease (P < 0.0001) scores were indepen

255 lity following recurrence included model for end-stage liver disease at LT >23, time to recurrence, >

256 ciated liver fibrosis is a critical step for end-stage liver disease progression.

257 onse rates, LT costs, and baseline Model for End-Stage Liver Disease score (DCC analysis only).

258 Cancer stage D ( P < .001), higher Model for End-Stage Liver Disease Sodium scores ( P < .001), highe

259 in treating kidney failure in patients with end-stage liver disease.

260 In end-stage mesothelioma, silencing of p16/Ink4a is sustai

261 HT2B/C receptors and abolished spasticity in end-stage mice.

262 Total joint replacements for end-stage osteoarthritis of the hip and knee are cost-ef

263 of patients with CKD, especially those with end-stage renal disease (ESRD), are controversial.

264 ECR was associated with development of end-stage renal disease (ESRD).

265 result of longer survival, the prevalence of end-stage renal disease in HIV is increasing.

266 e of a reduced risk of future progression to end-stage renal disease.

267 k factors of upper limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism, or even sy

268 tial influence on the time to development of end-stage TB.

269 dylation, and guanylation of U6 and Y RNA 3' ends, suggesting that in mammalian cells, the formation

270 eart failure, and increased left ventricular end-systolic dimension zscore at diagnosis were independ

271 e right atrial volume than right ventricular end-systolic volume in AF-TR (P<0.001).

272 icant reduction of left ventricular volumes (end-systolic volume: -4.3 [11.3] versus 7.4 [11.8], P=0.

273 ChIA-PET, in which the length of the paired-end tags is increased (up to 2 x 250 bp).

274 To this end, the amounts of amyloid-beta species and other prote

275 Toward this end, the availability of DNA sequence data from 60,706 p

276 tted to eliminating measles by 2012; to this end, the country enhanced its mandatory vaccination prog

277 To that end, the effects of various gene deletions or chemical b

278 such that the edge lengths are given by the end-to-end distances between nodes.

279 peropyrene adopts a twisted backbone with an end-to-end twist angle of 28 degrees that was unambiguou

280 Both the end-Permian and end-Triassic mass extinctions also triggered abrupt shif

281 ene adopts a twisted backbone with an end-to-end twist angle of 28 degrees that was unambiguously con

282 nding site of CV-N than with the nonreducing end unit.

283 4th growth stage; however, at this stage the end-use is not indicated for raw consumption but mostly

284 than passenger transportation or other major end-use sectors, with the magnitude of growth dependent

285 files for protein structures provided by the end user.

286 To this end, using an empirical approach and a simple conceptual

287 SE structure, especially of the pore-rich end walls, has a direct effect on translocation efficien

288 To this end we developed a nanoparticle (NP) platform, which is

289 To this end, we combined double-blind, placebo-controlled pharma

290 To this end, we developed a novel hydrosoluble zwitterionic MMP

291 To this end, we have simulated hundreds of spontaneous subunit r

292 To this end, we paired a sensory interference paradigm with an e

293 To this end, we show how intelligent sampling of the design spac

294 To this end, we test a cocktail of three virulent phages in two

295 To this end, we tested the effect of a newly developed molecule

296 To this end, we used genetically encoded probes consisting of th

297 Drosophila Fhod binds tightly to barbed ends, where it slows elongation in the absence of profil

298 ein interactions at microtubule (MT) growing ends, which has a fundamental role in MT polymerisation.

299 ran sulfate with characteristic non-reducing ends, which is present at birth in the mutant mice.

300 and the joining of newly excised transposon ends with target DNA.